A multicenter randomized phase II study of trastuzumab biosimilar (CT-P6) and chemotherapy (SOX or CapeOX) in HER2-positive advanced/recurrent gastric cancer (KSCC: TROX study).
Teppei Yamada, Yuichiro Nakashima, Tomomi Kashiwada, Hideto Sonoda et autres